Gebremedhin Gebremicael1,2, Desta Kassa1, Edwin Quinten3, Yodit Alemayehu1, Atsbeha Gebreegziaxier1, Yohannes Belay1, Debbie van Baarle4, Tom H M Ottenhoff3, Jacqueline M Cliff2, Mariëlle C Haks3. 1. HIV and TB Diseases Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. 2. TB Centre and Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom. 3. Department of Infectious Diseases, Leiden University Medical Center, Leiden. 4. Center for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Abstract
Background: Limitations in diagnostic tools to discriminate between active tuberculosis and latent Mycobacterium tuberculosis infection and for monitoring antituberculosis treatment responses are major challenges in tuberculosis control, especially in human immunodeficiency virus (HIV)-coinfected individuals. Methods: Expression levels of 105 immune-related genes were determined in 131 HIV-infected patients with active tuberculosis (n = 48), patients with latent M. tuberculosis infection (LTBI; n = 37), and controls with no M. tuberculosis infection (n = 46) in Addis Ababa, Ethiopia, using focused gene expression profiling with a dual-color reverse-transcription multiplex ligation-dependent probe amplification assay. Results: Within the cohort of HIV-positive subjects, the expression profiles of 7 genes at baseline (FCGR1A, RAB24, TLR1, TLR4, MMP9, NLRC4, and IL1B) could accurately discriminate between active tuberculosis and both latent and no M. tuberculosis infection, largely independently of (in)eligibility for highly active antiretroviral therapy (HAART). Six months after antituberculosis treatment, biomarker profiles of patients with tuberculosis became indistinguishable from those of patients with LTBI and controls. Importantly, host gene expression kinetics during antituberculosis treatment in HIV-coinfected individuals was found to be independent of HAART use. Conclusions: Blood transcriptomic profiles can potentially be used as biomarkers to discriminate the different clinical stages of tuberculosis in HIV-coinfected individuals and to monitor tuberculosis treatment responses in both HAART recipients and untreated individuals.
Background: Limitations in diagnostic tools to discriminate between active tuberculosis and latent Mycobacterium tuberculosis infection and for monitoring antituberculosis treatment responses are major challenges in tuberculosis control, especially in human immunodeficiency virus (HIV)-coinfected individuals. Methods: Expression levels of 105 immune-related genes were determined in 131 HIV-infectedpatients with active tuberculosis (n = 48), patients with latent M. tuberculosis infection (LTBI; n = 37), and controls with no M. tuberculosis infection (n = 46) in Addis Ababa, Ethiopia, using focused gene expression profiling with a dual-color reverse-transcription multiplex ligation-dependent probe amplification assay. Results: Within the cohort of HIV-positive subjects, the expression profiles of 7 genes at baseline (FCGR1A, RAB24, TLR1, TLR4, MMP9, NLRC4, and IL1B) could accurately discriminate between active tuberculosis and both latent and no M. tuberculosis infection, largely independently of (in)eligibility for highly active antiretroviral therapy (HAART). Six months after antituberculosis treatment, biomarker profiles of patients with tuberculosis became indistinguishable from those of patients with LTBI and controls. Importantly, host gene expression kinetics during antituberculosis treatment in HIV-coinfected individuals was found to be independent of HAART use. Conclusions: Blood transcriptomic profiles can potentially be used as biomarkers to discriminate the different clinical stages of tuberculosis in HIV-coinfected individuals and to monitor tuberculosis treatment responses in both HAART recipients and untreated individuals.
Authors: Faten Ahmad Alsulaimany; Nidal M Omer Zabermawi; Haifa Almukadi; Snijesh V Parambath; Preetha Jayasheela Shetty; Venkatesh Vaidyanathan; Ramu Elango; Babajan Babanaganapalli; Noor Ahmad Shaik Journal: Front Med (Lausanne) Date: 2022-02-07
Authors: Gebremedhin Gebremicael; Desta Kassa; Yodit Alemayehu; Atsbeha Gebreegziaxier; Yonas Kassahun; Debbie van Baarle; Tom H M Ottenhoff; Jacqueline M Cliff; Mariëlle C Haks Journal: PLoS One Date: 2019-12-10 Impact factor: 3.240
Authors: Maria Tió-Coma; Anouk van Hooij; Kidist Bobosha; Jolien J van der Ploeg-van Schip; Sayera Banu; Saraswoti Khadge; Pratibha Thapa; Chhatra B Kunwar; Isabela M Goulart; Yonas Bekele; Deanna A Hagge; Milton O Moraes; Rosane M B Teles; Roberta Olmo Pinheiro; Erik W van Zwet; Jelle J Goeman; Abraham Aseffa; Mariëlle C Haks; Tom H M Ottenhoff; Robert L Modlin; Annemieke Geluk Journal: Sci Rep Date: 2019-11-29 Impact factor: 4.379
Authors: Dhêmerson Souza De Lima; Caio C B Bomfim; Vinícius N C Leal; Edione C Reis; Jaíne L S Soares; Fernanda P Fernandes; Eduardo P Amaral; Flavio V Loures; Mauricio M Ogusku; Maria R D'Imperio Lima; Aya Sadahiro; Alessandra Pontillo Journal: Front Immunol Date: 2020-10-21 Impact factor: 7.561